Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Filorexant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 known ✓ | O43614 | 8/20 | 1.00 |
| ▸ | HCRTR1 known ✓ | O43613 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Filorexant SCHEMBL1717116 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| Filorexant SCHEMBL1716633 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| Filorexant SCHEMBL1716875 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| Filorexant SCHEMBL1716783 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL2342737 | 0.95 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL1716753 | 0.94 | HCRTR2 (0.89) | HCRTR2HCRTR1 | |
| SCHEMBL1716867 | 0.94 | HCRTR2 (0.89) | HCRTR2HCRTR1 | |
| SCHEMBL12411902 | 0.93 | HCRTR2 (0.87) | HCRTR2HCRTR1 | |
| SCHEMBL1716792 | 0.92 | HCRTR2 (0.84) | HCRTR2HCRTR1 | |
| SCHEMBL1717341 | 0.92 | HCRTR2 (0.84) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569311-B2 | Pyridyl piperidine orexin receptor antagonists | Merch Sharp & Dohme Corp. (US) | 2013-10-29 | — | — | US | claimed |
| US-20120295921-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-11-22 | — | — | US | claimed |
| EP-2152690-B1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-01-11 | — | — | EP | claimed |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | claimed |
| EP-2152690-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008147518-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-12-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295921-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HCRTR1 2/4885 |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.